AstraZeneca Says Imfinzi Data Shows Improved Response in Gastric Cancers
Provided by
Dow Jones
By Michael Susin
AstraZeneca said late Friday that interim analysis of the phase III study regarding its Imfinzi drug together with chemotherapy significantly improved pathologic complete response in gastric and gastroesophageal junction cancers.
The Anglo-Swedish pharma giant said that the trial demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of pathologic complete response in patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction cancers.
The company said that the trial will continue as planned to assess overall survival data.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
June 02, 2023 12:28 ET (16:28 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
Will Earnings From These 10 AI Stocks Live Up to the Hype?
-
What’s Happening In the Markets This Week
-
What the Next Bitcoin Halving Means for ETF Investors
-
Going Into Earnings, Is Microsoft a Buy, a Sell, or Fairly Valued?
-
March PCE Inflation Index Forecasts Show Mixed Readings On Price Pressures
-
After Earnings, Is Charles Schwab Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Apple Stock a Buy, a Sell, or Fairly Valued?
-
AT&T Earnings: Network Outage Didn’t Stop Solid Growth or Cash Flow
-
This Dividend Stock With a Nearly 7% Yield Is a Buy After Selloff
-
Visa Earnings: Growth Holds Steady
-
GM Earnings: Strong Start to 2024 Is Good Sign for Rest of the Year
-
Tesla Stock Undervalued as Outlook Improves